Codexis Inc Stock Price, News & Analysis

Codexis (CDXS) and Kalsec have expanded their research collaboration, entering into an exclusive supply agreement for a new enzyme aimed at producing Kalsec's latest natural hop acid. This enzyme, developed using Codexis’ CodeEvolver technology, enhances functionality, stability, and efficiency, enabling commercial-scale production by early 2022. The partnership aims to create innovative, sustainable bioprocesses, contributing to product differentiation in the competitive food and beverage market. Both companies emphasize sustainability and the potential for reduced manufacturing costs.

Codexis, Inc. (Nasdaq:CDXS) will announce its Q2 2021 financial results on August 5, 2021. A conference call will follow at 4:30 p.m. ET for discussion and updates. The company specializes in enzyme engineering and aims to enhance sustainable manufacturing across various sectors, including pharmaceuticals and food. Their proprietary CodeEvolver® platform drives innovation in biotherapeutics and diagnostics while improving resource efficiency. Investors can access the live call via the Codexis Investor Relations website.

Codexis, Inc. (CDXS) announced the successful completion of its CodeEvolver® platform technology transfer to Novartis Pharma AG. This collaboration, initiated in May 2019, allows Novartis to utilize CodeEvolver® for developing high-performance enzymes in pharmaceutical manufacturing. The new enzymes promise reduced capital requirements, higher yields, and lower energy usage compared to conventional chemistry methods. Codexis has now achieved three similar collaborations, with this being the first conducted virtually due to the pandemic's challenges.

Codexis (Nasdaq: CDXS) announced a milestone payment from GlaxoSmithKline related to its CodeEvolver® protein engineering platform. This payment, recognized as revenue in Q2 2021, signifies progress in the licensing agreement for an enzyme aimed at enhancing drug manufacturing. Codexis continues to strengthen its partnership with GSK, emphasizing the potential for significant long-term revenue from CodeEvolver. The company manages relationships with three leading pharmaceutical firms, indicating a promising outlook for enzyme commercialization and synthetic biology applications.

Codexis (Nasdaq: CDXS) increases its 2021 revenue guidance to $89-$93 million, up from $82-$85 million, after securing a $13.9 million purchase order for its high-performance enzyme product from a global pharmaceutical company. Product revenue guidance is also raised to $45-$48 million from $36-$39 million, with gross margin expectations now at 60%-64%, up from 54%-58%. This growth reflects Codexis' capacity to enhance revenue and margin through its innovative enzyme engineering platform.

Codexis announced an expanded collaboration with Takeda Pharmaceutical for gene therapy development, increasing its programs from three to four. The initial agreement leveraged Codexis' CodeEvolver platform to create enzyme variants aimed at treating rare genetic disorders such as Fabry and Pompe Diseases. Under the agreement, Codexis will receive upfront payments, R&D reimbursements, milestone payments, and royalties on sales. The partnership showcases significant progress in engineering genetic sequences, reflecting potential advancements in treating lysosomal storage disorders.

Codexis (Nasdaq:CDXS), a leader in enzyme engineering, will participate in three virtual investment conferences. Key events include the Jefferies Virtual Healthcare Conference on June 1, 2021, featuring a live webcast, and the Craig-Hallum Institutional Investor Conference on June 2, 2021, with 1x1 investor meetings. Additionally, management will join a panel discussion at the Piper Sandler SynBio Day on June 23, 2021. Codexis leverages its CodeEvolver platform to develop high-performance enzymes that enhance sustainability in pharmaceuticals, food, and industrial production.

Codexis (Nasdaq: CDXS) announced its participation in three upcoming virtual investment conferences on May 17, 2021. The events include the UBS Global Healthcare Virtual Conference on May 24 at 11:00 a.m. ET, featuring a corporate presentation available via live webcast. The SynBioBeta Synthetic Biology Biopharma Conference follows on May 26 at 11:10 a.m. ET, focusing on biopharma expectations for 2025. Also on May 26, Codexis will attend the Benchmark Company Healthcare House Call Conference and host one-on-one investor meetings.

Codexis specializes in enzyme engineering for sustainable manufacturing and biotherapeutics.

Codexis, Inc. (CDXS) reported a 23% increase in total revenue for Q1 2021, totaling $18.0 million, with product revenue doubling to $10.2 million. Notable growth was seen in the Performance Enzymes segment, which generated $14.2 million. The company's gross margin on product sales improved to 59%, up from 50% last year. Despite this growth, Codexis reported a net loss of $9.1 million or $0.14 per share. For 2021, the company maintains revenue guidance between $82 million and $85 million.